Exudative retinopathy – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 28 May 2026 10:59:51 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Exudative retinopathy – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Bevacizumab Injections for Patients with Coats’ Disease https://clinicaltrials.eu/trial/study-on-bevacizumab-injections-for-patients-with-coats-disease/ Wed, 29 Apr 2026 14:58:09 +0000 https://clinicaltrials.eu/trial/study-on-bevacizumab-injections-for-patients-with-coats-disease/ This clinical trial is focused on studying a rare eye condition called Coats’ disease. This disease affects the blood vessels in the retina, which is the light-sensitive layer at the back of the eye, and can lead to vision problems. The study is investigating the use of a treatment called Avastin, which contains the active substance bevacizumab. Avastin is given as an injection directly into the eye, a method known as intravitreal injection. The purpose of the study is to compare the effectiveness of Avastin with a standard treatment called laser photocoagulation, which uses a laser to seal off abnormal blood vessels in the eye.

Participants in the study will receive either the Avastin injections or the laser treatment. The study will last for about six months, during which the progress of the disease will be monitored. The main goal is to see if Avastin can improve the condition of the eye by at least one stage, according to a specific classification system used by eye doctors. The study will also look at other factors, such as changes in vision and the thickness of the retina, to understand the overall impact of the treatment.

Throughout the study, participants will have regular check-ups to assess their eye health and any changes in their condition. The study aims to provide valuable information on whether Avastin can be a beneficial treatment option for people with Coats’ disease, potentially offering an alternative to the current standard treatment. This research could help improve the management of this rare eye condition and enhance the quality of life for those affected by it.

]]>